This editorial argues that journals, funders and scientists must actively embrace non-animal methods because the momentum for alternative testing approaches has become irreversible
The 3Rs Collaborative initiative highlights the need for regulators, developers and end-users to collaborate in order to accelerate regulatory adoption of microphysiological systems (MPS).
This post reviews how new-approach methodologies (NAMs) for developmental toxicity are gaining traction in pharma, especially under the forthcoming ICH S5 (R3) guideline pathway
This article explores how the poor predictive value of animal studies for human outcomes is driving momentum toward animal-free research methods
The blog explains how pharmaceutical firms can align with the FDA Roadmap and deploy NAMs as the default approach for investigational drugs, replacing animal studies
The blog outlines the U.S. Food & Drug Administration’s 2025 ‘Roadmap to Reducing Animal Testing’, mapping a 3-5 year transition to non-animal methods for preclinical safety studies
The post highlights key regulatory and industry milestones (e.g., NIH funding shifts, NAMs workshops) marking the advance of animal-free research via new approach methodologies (NAMs)
This Q&A blog surveys how human-relevant in vitro, ex vivo and in silico methods are becoming credible alternatives to animal models under evolving regulatory mandates
This article discusses the FDA’s 2025 announcement that animal testing requirements may be phased out in favour of NAMs, marking a major inflection point in pharmacology
The article describes how 3D cell-based models (spheroids, organoids, organs-on-chips) are transforming pre-clinical development by delivering more human-relevant data
In light of the 2025 Nobel Prize in immune tolerance, this blog links the award’s science to the importance of immune-competent 3D in vitro models for translational research
This piece from NC3Rs describes how regulators, academia and industry are working together to embed NAMs in medicines development and reduce reliance on animal tests
The blog provides a legal commentary on how the Food and Drug Cosmetic Act and the FDA Modernization Act 2.0 enable alternatives to animal testing and cautions against over-hyped expectations around regulatory change.
This FDA page outlines the agency’s commitment to alternative methods for safety testing and provides guidance on how new approach methodologies (NAMs) fit into the regulatory ecosystem
This FDA resource gives practical guidance for implementing alternative methods (NAMs) in drug development, including qualification pathways and regulatory submission consideration
Building regulatory and scientific trust in new-approach methodologies through collaborative, evidence-based validation efforts